Search the Newsreel

Apogee Therapeutics (NASDAQ:APGE) Stock Rating Lowered by BTIG Research

BTIG Research has downgraded Apogee Therapeutics (NASDAQ:APGE) from a "buy" to a "neutral" rating. This follows a broader trend of analysts issuing "Hold" ratings, with the consensus price target at $121.25, despite the company's shares opening near their 52-week high and reporting a quarterly …

Apogee Therapeutics (APGE): Fairmount-linked funds exercise 42,208 options

Fairmount-affiliated entities reported exercising options to acquire 42,208 shares of Apogee Therapeutics (APGE) common stock on August 7, 2026, at strike prices of $17.00 and $43.85 per share. These shares are held indirectly through Fairmount Healthcare Fund II L.P., with Tomas Kiselak and Peter …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

Investors often weigh high-margin drug developers against massive healthcare service providers when building a portfolio. Choosing between AbbVie (NYSE:ABBV) and CVS Health (NYSE:CVS) requires balancing biotech growth against retail stability. AbbVie focuses on discovering and commercializing advanced therapies, while CVS Health operates an integrated …

Apogee Therapeutics (APGE) details Q2 2026 losses, AbbVie merger plan and $100M BXLS deal

Apogee Therapeutics (NASDAQ:APGE) Issues Earnings Results, Misses Expectations By $1.00 EPS

Apogee Therapeutics (NASDAQ:APGE) reported a quarterly loss of $2.07 per share, missing analyst expectations by $1.00, as the consensus called for a $1.07 loss. Following the announcement, several analysts downgraded the stock or adjusted their price targets. Insiders have sold approximately $22.0 million worth …

Apogee Therapeutics 2Q 2026: Net loss $85.9M, First half loss $160M — 10-Q Summary

Apogee Therapeutics, Inc. reported a consolidated net loss of $85.9M for Q2 2026 and $160M for the first half of 2026, marking an increase from the previous year, as the company has no product sales. Despite the losses, the company highlighted positive Phase 2 …

Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates

Apogee Therapeutics announced its second quarter 2026 financial results and provided updates on its corporate and pipeline developments. The company reported a pending acquisition by AbbVie for $135.11 per share, totaling approximately $10.9 billion, and positive 16-week Phase 2 APEX Part B results for …

Apogee Enterprises, Inc. $APOG Shares Purchased by Sei Investments Co.

Apogee Therapeutics Inc. $APGE Shares Acquired by Bank of America Corp DE

Bank of America Corp DE increased its stake in Apogee Therapeutics Inc. (NASDAQ:APGE) by 13.5% in the first quarter, now holding 900,871 shares valued at $75.8 million. Despite this institutional interest, company insiders, including CEO Michael Henderson, sold over 180,000 shares totaling approximately $22 …

Apogee Therapeutics (APGE) Earnings Date and Reports 2026 $APGE

Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares

Carl Dambkowski, an insider at Apogee Therapeutics (NASDAQ:APGE), sold 5,500 shares of the company's stock for approximately $737,935. This sale, conducted under a Rule 10b5-1 plan, reduced his ownership by 3.16% to 168,498 shares. The company's stock traded up 0.3% to $134.84, near its …

Apogee Therapeutics CMO Carl Dambkowski sells $737,934 in shares

Carl Dambkowski, CMO at Apogee Therapeutics, sold 5,500 shares for $737,934 and acquired 4,125 shares via option exercise for $94,297. These transactions occurred under a pre-arranged trading plan, with the stock trading near its 52-week high and appearing overvalued. The company is also in …

Apogee Therapeutics (APGE) CMO trades stock under 10b5-1 plan

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, exercised stock options for 4,125 shares at $22.86 per share and simultaneously sold 5,500 shares at $134.17 per share on August 5, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted in September 2025. …

Sei Investments Co. Grows Stock Holdings in Apogee Therapeutics Inc. $APGE

Sei Investments Co. significantly increased its stake in Apogee Therapeutics Inc. by 158.5% in the first quarter, bringing its total holdings to 42,203 shares valued at approximately $3.55 million. While institutional ownership of APGE is high at 79.04%, company insiders have sold a substantial …

Apogee Enterprises Inc (APOG) Stock News Today

This page provides current stock news and financial data for Apogee Enterprises Inc (APOG). It includes real-time stock quotes, market capitalization, P/E ratio, and highlights that more news and analysis are coming soon. The stock closed at $43.520 with a slight gain on August …

(APOG) Movement as an Input in Quant Signal Sets

This article analyzes Apogee Enterprises Inc. (APOG) using AI models to generate trading strategies and multi-timeframe signal analysis. It highlights strong near and mid-term sentiment, potential for long-term extension, and identifies compelling upside potential with no resistance levels above the current price. The report …

Apogee Enterprises Inc (APOG) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for Apogee Enterprises Inc (APOG), noting its current earnings forecast score and industry ranking. It details analyst ratings, price targets, and expected EPS and revenue figures for upcoming quarters. The consensus among analysts is a "Buy" trend for …

Apogee Therapeutics stock hits all-time high at 134.47 USD

Apogee Therapeutics stock has reached an all-time high of $134.47, reflecting a significant 270% 1-year return and a market cap of $10.08 billion. This surge comes as the company is set to be acquired by AbbVie for $135.11 per share, valuing it at approximately …

PMC Files Amended Lawsuit Against Apogee, Wausau and Viracon Over Defective Glass

PMC Property Group has filed an amended lawsuit against Apogee Enterprises and its subsidiaries, Wausau Group and Viracon Inc., alleging defective glass in three Philadelphia high-rise residential buildings. The lawsuit claims the defendants are avoiding responsibility for the spontaneous shattering of windows, which PMC …

Apogee Therapeutics, Inc. (APGE) Stock Price, News, Quote & History

Apogee Therapeutics, Inc. (APGE) is a clinical-stage biotechnology company focused on developing novel biologics for inflammatory and immunology indications. The article provides current stock performance, key financial metrics, analyst ratings, and a company overview, highlighting its drug candidates like Zumilokibart (APG777) in clinical trials …

Two Public-Company CEOs Take Seats on Apogee Enterprises' Board

Apogee Enterprises, Inc. (Nasdaq: APOG) has expanded its Board of Directors from six to eight members by appointing Joseph B. Hayek, President and CEO of Worthington Enterprises, Inc., and Suresh Krishna, President and CEO of Proto Labs, Inc., as independent directors. These additions, effective …

This Stock Keeps Raising Its Dividend No Matter What the Market Does -- and Wall Street Thinks It's a Buy Right Now

Key Points AbbVie posted solid second-quarter financial results, led by its two most important products, Skyrizi and Rinvoq. The company's portfolio and pipeline should help maintain steady revenue and earnings over the medium term. AbbVie has increased its payouts for over 50 consecutive years. …

Apogee Enterprises adds two CEOs to board of directors By Investing.com

Apogee Enterprises, Inc. (NASDAQ:APOG) has expanded its board of directors from six to eight members with the appointment of two new independent directors. Joseph B. Hayek, President and CEO of Worthington Enterprises, Inc., and Suresh Krishna, President and CEO of Proto Labs, Inc., have …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital's Baron Health Care Fund exited its position in Apogee Therapeutics (APGE) after the company announced an agreement to be acquired by AbbVie Inc. for $135.11 per share. The acquisition, representing a 49.5% premium, led to the fund selling its shares. Despite this, …

Dimensional Fund Advisors LP Has $35.67 Million Stock Position in Apogee Enterprises, Inc. $APOG

Dimensional Fund Advisors LP increased its stake in Apogee Enterprises (NASDAQ:APOG) by 7.9% to 1.06 million shares, valuing their position at $35.67 million. The industrial products company exceeded quarterly EPS estimates with $0.57, though revenue saw a slight year-over-year decline. Analysts maintain a "Buy" …

Arrowstreet Capital Limited Partnership Takes $2.66 Million Position in Apogee Enterprises, Inc. $APOG

Arrowstreet Capital Limited Partnership has acquired 79,388 shares of Apogee Enterprises (NASDAQ:APOG), valued at approximately $2.66 million, establishing a new position in the industrial products company. This investment highlights institutional interest, with such investors now owning 94.05% of Apogee. The move follows recent analyst …

Why (APGE) Price Action Is Critical for Tactical Trading

This article analyzes Apogee Therapeutics Inc. (NASDAQ: APGE) for tactical trading, indicating a neutral near and mid-term outlook but a positive long-term bias. It outlines three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes …

Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?

Apogee Therapeutics (APGE) has seen significant returns recently, but its valuation checks indicate it is currently expensive, scoring 1 out of 6 on Simply Wall St.'s valuation scale. The company's stock trades at a high price-to-book ratio compared to the biotech industry average, suggesting …

Apogee Therapeutics (APGE) Holds Onto Strong Momentum, Is Its 8x P B Fair?

Apogee Therapeutics (APGE) to Post Quarterly Earnings on Monday

AbbVie Quietly Solved Its Biggest Problem—Now What?

Key Points Interested in AbbVie Inc.? Here are five stocks we like better. AbbVie posted strong Q2 revenue and earnings growth, driven by its Immunology and Neurosciences segments. Analysts maintain a Moderate Buy consensus with a 76% buy-side bias, and institutional buying trends suggest …

Segall Bryant & Hamill LLC Reduces Stock Position in Apogee Enterprises, Inc. $APOG

Segall Bryant & Hamill LLC significantly reduced its stake in Apogee Enterprises (NASDAQ:APOG) by 46.8% in Q1 2026, selling over 421,000 shares but still retaining shares worth approximately $16.1 million. Despite this reduction, institutional investors collectively hold 94.05% of Apogee's stock. The company recently …

Perceptive Advisors LLC Has $129.65 Million Stock Holdings in Apogee Therapeutics Inc. $APGE